Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT05427084

Canagliflozin Targeting Vascular Inflammation

Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-06

24

Participants Needed

1

Research Sites

106 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

CONDITIONS

Official Title

Canagliflozin Targeting Vascular Inflammation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Stable coronary artery disease more than 60 days after myocardial infarction
  • Diagnosis of diabetes
  • Provided informed consent
Not Eligible

You will not qualify if you...

  • Severe left ventricular dysfunction with ejection fraction less than 50%
  • Decompensated heart failure
  • Active infections such as pneumonia or skin infections requiring antibiotics
  • Active inflammatory diseases or use of systemic anti-inflammatory therapy
  • Pregnancy or breastfeeding
  • Women of childbearing potential not using two forms of contraception or men not using contraception
  • Glomerular filtration rate below 50 ml/min/1.72m2
  • Use of certain medications like p-glycoprotein inhibitors or strong CYP3A4 inhibitors
  • Low hemoglobin, white blood cell, or platelet counts
  • History of severe liver disease or elevated liver enzymes
  • Unable to give informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Ottawa Heart Institute

Ottawa, Ontario, Canada, K1Y 4W7

Actively Recruiting

Loading map...

Research Team

K

Kevin Boczar, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here